Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Conditions:   Diffuse Astrocytoma, IDH-Mutant;   Glioblastoma, IDH-wildtype;   Brain Metastases, Adult;   Cervical Cancer;   Colorectal Cancer;   Esophageal Cancer;   Esophageal Squamous Cell Carcinoma;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Head and Neck Squ amous Cell Carcinoma;   Melanoma;   Merkel Cell Carcinoma;   Microsatellite Instability-High Solid Malignant Tumor;   Mismatch Repair Deficient Solid Malignant Tumor;   Microsatellite Instability-High Colorectal Cancer;   Mismatch Repair Deficient Colorectal Cancer;   Non-smal l Cell Lung Cancer;   Renal Cell Carcinoma;   Small Cell Lung Cancer;   Squamous Cell Carcinoma;   Urothelial Carcinoma Interventions:   Drug: NEO212 Oral Capsule;   Drug: Ipilimumab;   Drug: Pembrolizumab;   Drug: Nivolumab;   Drug: Regorafenib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: FOLFIRI Protocol;   Drug: Bevacizumab Sponsor:   Neonc Technologies, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials